MetLife Investment Management’s Keros Therapeutics KROS Stock Holding History

MetLife Investment Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$184K	Hold	16,682	–	–	﹤0.01%	2271
2025 Q4	$340K	Sell	16,682 -3,067	-16%	-$53.8K	﹤0.01%	1982
2025 Q3	$312K	Hold	19,749	–	–	﹤0.01%	2058
2025 Q2	$264K	Buy	19,749 +1,651	+9%	+$22.3K	﹤0.01%	2031
2025 Q1	$184K	Hold	18,098	–	–	﹤0.01%	2243
2024 Q4	$286K	Buy	18,098 +1,027	+6%	+$53.4K	﹤0.01%	2102
2024 Q3	$991K	Hold	17,071	–	–	0.01%	1392
2024 Q2	$780K	Buy	17,071 +3,928	+30%	+$211K	﹤0.01%	1483
2024 Q1	$870K	Buy	13,143 +1,258	+11%	+$74.6K	0.01%	1377
2023 Q4	$473K	Hold	11,885	–	–	﹤0.01%	1720
2023 Q3	$379K	Hold	11,885	–	–	﹤0.01%	1799
2023 Q2	$478K	Buy	11,885 +1,788	+18%	+$78.4K	﹤0.01%	1718
2023 Q1	$431K	Hold	10,097	–	–	﹤0.01%	1733
2022 Q4	$485K	Buy	10,097 +1,642	+19%	+$76.7K	﹤0.01%	1663
2022 Q3	$318K	Hold	8,455	–	–	﹤0.01%	1970
2022 Q2	$234K	Hold	8,455	–	–	﹤0.01%	2206
2022 Q1	$460K	Buy	8,455 +2,999	+55%	+$154K	﹤0.01%	1823
2021 Q4	$319K	Hold	5,456	–	–	﹤0.01%	1776
2021 Q3	$216K	Hold	5,456	–	–	﹤0.01%	2043
2021 Q2	$232K	Hold	5,456	–	–	﹤0.01%	2065
2021 Q1	$336K	Hold	5,456	–	–	﹤0.01%	1748
2020 Q4	$385K	Buy	5,456 +1,646	+43%	+$104K	﹤0.01%	1607
2020 Q3	$147K	Hold	3,810	–	–	﹤0.01%	2036
2020 Q2	$143K	Buy	+3,810	New	+$117K	﹤0.01%	2079

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

MetLife Investment Management's KROS Position: Q1 2026 in Review

MetLife Investment Management held its Keros Therapeutics (KROS) position steady in Q1 2026 at 16,682 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

MetLife Investment Management first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $991K in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

MetLife Investment Management held 16,682 shares of Keros Therapeutics worth $184K as of Q1 2026.
MetLife Investment Management left its Keros Therapeutics share count unchanged in Q1 2026.
Keros Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2271 holding.
MetLife Investment Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
MetLife Investment Management's Keros Therapeutics position peaked at $991K in Q3 2024.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.